尿微量白蛋白/肌酐在卵巢癌患者联合化疗中对肾脏损害的早期预警价值  

Clinical significance of microalbuminuria/creatinine for earlier diagnosis of kidney lesion in patients with ovary carcinoma in union chemotherapy

作　　者：夏志军[1] 于欢[2] 付丽[1] 周卓[1] 

机构地区：[1]中国医科大学附属盛京医院妇产科,辽宁沈阳110001 [2]北京中日友好医院妇产科,北京100029

出　　处：《中国现代医学杂志》2009年第11期1702-1704,共3页China Journal of Modern Medicine

基　　金：辽宁省自然基金(No:2005008)

摘　　要：目的探讨尿微量白蛋白/肌酐(mALB/Cr)值在在卵巢癌患者联合化疗中对肾脏损害的早期预警价值。方法利用尿mALB/Cr分析仪检测36例卵巢癌患者术后联合化疗第1、2、3疗程前后mALB/Cr值,同时测定血BUN、Cr值。结果36例卵巢癌患者术后1～3个疗程化疗前后Alb/Cr值变化明显(P<0.05和P<0.01)差异有显著性;血BUN、Cr均无明显变化(P>0.05)差异无显著性。结论尿mALB/Cr值能够较早预警卵巢癌患者术后联合化疗对肾脏的损害。[Objective] To study the clinical significance of mALB/Cr in urine on earlier period diagnosis of kidney lesion in union chemotherapy to patients with ovary carcinoma. [Methods] By mALB/Cr analysis-meter, the urine mALB and Cr and blood BUN and Cr of 36 cases of ovary carcinoma were analysed before and 24-48 h after union chemotherapy from first to third course. [Results] Statistical significance （P 〈0.05） of urine mALB/Cr were observed in 36 eases with ovary carcinoma before and 24-48 h after union chemotherapy. In comparison, the blood BUN and Cr had no apparent variation before and after the union chemotherapy. [Conclusion] As an earlier forcewarn standard for renal function evaluation, especially for slight impairment, the urine mALB/Cr is more sensitive than the blood BUN and Cr.

关 键 词：尿微量白蛋白/肌酐 卵巢癌 化疗 肾功能 

分 类 号：R737.31[医药卫生—肿瘤]